Navigation Links


RPA in Medical News

PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants

...velopment programs include: SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine Third generation rpa anthrax vaccine Valortim((R)) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection Protexia((R)) - a ...

Renal Physicians Association Participates in PEAK Campaign

...d Accountability in Kidney Care (PEAK) initiative. rpa is a member of KCP, a coalition which includes gro...mmend KCP for launching the PEAK initiative," said rpa President Dr. Edward Jones. "While the evidence b... in the overall improvement of CKD care quality." rpa has developed evidence-based clinical practice gui...

PharmAthene Reports Year End 2008 Financial Results

...t contracts supporting the development of SparVax(TM), our third generation rpa anthrax vaccine candidate, and RypVax(TM). Research and development ex... - a recombinant dual antigen vaccine for plague A third generation rpa anthrax vaccine. For more information about PharmAthene, ...

The Renal Physicians Guide to Nephrology Practice, 6th Edition

...nsure quality care under the highest standards of medical practice for patients with kidney disease and related disorders. For more information about rpa please visit www.renalmd.org or call 301-468-3515. ...

Cogdell Spencer Breaks Ground on Projects in Tennessee and North Carolina

...cian groups. Erdman is the developer on the project, Robins & Morton of Birmingham, Alabama is the general contractor on this project while rpa Design, based in Charlotte, North Carolina, is the project architect on both the Tennessee and Mebane projects. Upon completion, Cogdell Spencer Inc....

Renal Physicians Association 2009 Annual Meeting

...and relevant to today's nephrology practitioners. rpa will convene national leaders and experts in their... Beyond the rich and pertinent content that the rpa meeting offers, this unique venue allows nephrolog...rapple with every day. Register today for the 2009 rpa Annual Meeting March 20-23 in Baltimore, Maryland ...

Iomai Wins Department of Defense Grant to Develop a Stable, Patch-Based Anthrax Vaccine

... UK site has been developing processes and making protein-based biopharmaceuticals to cGMP since 1998. Process development and cGMP manufacture of the rpa anthrax vaccine and the plague vaccine have been carried out at this site since 2000. Avecia Biotechnology Inc. is a leader in the field of contract m...

More>>

RPA in Medical Technology

PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program

ANNAPOLIS, Md., April 28 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP ) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it will be hosting a conference call for investors on Wednesday, April 29th beginning at ...

PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)

...tality associated with exposure to chemical nerve agents RypVax(TM) - a recombinant dual antigen vaccine for plague A third generation rpa anthrax vaccine. For more information about PharmAthene, please visit www.PharmAthene.com . Statement on Cautionary Factors ...

PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA

... and procure 25 million doses of a next generation rpa anthrax vaccine for the country's civilian biomedi...ced development and procurement of next generation rpa anthrax vaccines." About SparVax(TM) Spar...gen (rPA) anthrax vaccine Third generation rpa anthrax vaccine Valortim(R) - a fully huma...

Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology

...tality associated with exposure to chemical nerve agents RypVax(TM) - a recombinant dual antigen vaccine for plague A third generation rpa anthrax vaccine. For more information about PharmAthene, please visit www.PharmAthene.com . Statement on Cautionary Factors ...

PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)

...t development programs include: -- SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine -- Third generation rpa anthrax vaccine -- Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection -- Protexia(R) - a nove...

PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop

... development programs include: -- SparVax(TM) -- a second generation recombinant protective antigen (rPA) anthrax vaccine -- Third generation rpa anthrax vaccine -- Valortim(R) -- a fully human monoclonal antibody for the prevention and treatment of anthrax infection -- Protexia(R) -- a no...

ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.

...s rPA102 anthrax vaccine is composed of a purified rpa and an aluminum salt adjuvant routinely used in ma...l be mirrored in testing of Viprovex with VaxGen's rpa antigen." Initial studies in a well-established m...chael Wilhelm. "With the previous success that the rpa vaccine has seen in the lab against anthrax we are...
RPA in Biological News

Kidney function discovery sheds light on genetic complexity of disease

... due to an inherited abnormality of a specific pump on the surface of kidney cells," Professor Rasko explains. The teams from Centenary Institute, rpa and ANU have now unravelled the genetic explanation by showing that not one, but up to four different pumps present in the kidney determine whether or...

DNA ends: Common tool, different job

... Stn1, they dug up Rpa2, the middle subunit of the rpa complex. In particular, Stn1 and Rpa2 share simila...e just like their counterparts in the conventional rpa complex. However, Stn1 and Ten1 have the same pred...tial biological parallels between the conventional rpa complex and the newly discovered t-RPA complex. ...
RPA in Biological Technology

PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review

ANNAPOLIS, Md., July 9 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Company's propos...

PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program

ANNAPOLIS, Md., Sept. 26 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Inst...

PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009

...elopment programs include: SparVax(TM) -- a second generation recombinant protective antigen (rPA) anthrax vaccine Third generation rpa anthrax vaccine Valortim((R)) -- a fully human monoclonal antibody for the prevention and treatment of anthrax infection Protexia((R)) -- ...

PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants

... programs include: SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine Third generation rpa anthrax vaccine Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection Pr...

PharmAthene Reports First Quarter 2009 Financial and Operational Results

... activities related to the SparVax(TM), RypVax(TM) and our third generation rpa anthrax vaccine programs, which we acquired in the second quarter of 2008. ...combinant protective antigen (rPA) anthrax vaccine Third generation rpa anthrax vaccine Valortim(R) - a fully human monoclonal antibody for...

PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research

...t programs include: SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine Third generation rpa anthrax vaccine Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection Protexia(R) - a ...

PharmAthene Announces $5.5 Million Public Equity Offering

...t programs include: SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine Third generation rpa anthrax vaccine Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection Protexia(R) - a ...

PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009

...t programs include: SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine Third generation rpa anthrax vaccine Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection Protexia(R) - a ...

PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting

...These results suggest that SparVax(TM) may be a promising second generation rpa anthrax vaccine candidate for civilian defense against anthrax infection. ...combinant protective antigen (rPA) anthrax vaccine Third generation rpa anthrax vaccine Valortim(R) - a fully human monoclonal antibody for...

PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel

...opment programs include: -- SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine -- Third generation rpa anthrax vaccine -- Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection -- Protexia(R...

More>>

RPA in Biological Dictionary

Primase

...subunits, which catalyzes the ... ... DnaB Helicase and Its Complex with a Domain of DnaG Primase [My Copy] ... posted to atr primase rad17 rfc rpa by DNAReplication on 2008-01-02 18:45:20 as ... The European ... DNA primase synthesizes the RNA primers for the Okazaki ... In Escherichia coli,...
Other TagsEndotoxinExhaustExhaustBeaconBeaconCatchCatchVerticalOrbitOrbit
(Date:12/1/2009)...ec. 1 The government of Mexico Cit...er for biomedical and nanomedical research, called...earch and development will be integrated with the ...Spanish speaking university in the world. The res...2010, has been designed by the internationally-acc...
(Date:12/1/2009)...sh., Dec 1 Edifecs, Inc., the prov...ernization solutions announced an enhanced release...PAA 4010A1 to HIPAA 5010 migrations. XEngine Trans...on maps, allows generation of test data and permit...roduction, thus addressing most requirements for o...
(Date:12/1/2009)...al and South America, study finds , , TU... of intensive care unit patients worldwide suffer ...the hospital, a new study finds. , Researchers ...07) on 13,796 patients, aged 18 and older, in 1,26... of patients were classified as infected and 71 pe...
(Date:12/1/2009)...because pandemic,s course remains unpredictable ,...U.S. health official said Tuesday that H1N1 swine ..., but many experts agreed the virus could return i...espread in 32 states -- down from 43 states the we...U.S. Centers for Disease Control and Prevention (C...
(Date:12/1/2009)...ractitioners of any medical, legal or business req... sigh of relief this week with the release of ,Dic...eleased over the holiday weekend, allows anyone re...to do so quickly and seamlessly using just the iPh...December 1, 2009 -- The iPhone App, released by Fl...
Breaking Medicine News(10 mins):Health News:Mexico City to Build World-Class Hub for Medical Research 2Health News:Edifecs Delivers Enhanced HIPAA 4010A1 to 5010 Migration Capabilities for Healthcare Organizations 2Health News:Edifecs Delivers Enhanced HIPAA 4010A1 to 5010 Migration Capabilities for Healthcare Organizations 3Health News:Half of ICU Patients Suffer From Infections 2Health News:Swine Flu Waning, But Could Return 2Health News:Swine Flu Waning, But Could Return 3Health News:Medical and Legal Professionals Find Relief Leveraging Apple iPhone App for Dictation and Transcription 'On the Go' 2
(Date:12/1/2009)...ust for listening to the radio anymore. They,re us...Research from North Carolina State University is r...ng shape-shifting antennas that open the door to a...fety to military deployment. , Modern antennas a... limitations to how far they can be bent and how ...
(Date:11/30/2009)...ganisation is needed to monitor the commitments th...gen to cut their deforestation rates, according to... government agencies and research groups have fail...images of the Earth,s surface collected each week ...blished by Dr Alan Grainger in the Proceedings of...
(Date:11/30/2009)...s of gravy and dessert at the holiday table are ev...y thought. According to a new research report rece...p://www.fasebj.org ), a diet that is high in fat a...tely cause our bodies to store too much fat. This ...the already difficult task of converting high-fat ...
Breaking Biology News(10 mins):Shape shifters: Researchers create new breed of antennas 2World forest observatory needed to monitor vital role of forests in climate deal 2Happy holidays from the groaning board; Western diets turn on fat genes 2University of Maryland Company Trauma Solutions Named Finalist in 24250K Draper Fisher Jurvetson and Cisco Systems Global Business Plan Competition 50088 1University of Maryland Company Trauma Solutions Named Finalist in 24250K Draper Fisher Jurvetson and Cisco Systems Global Business Plan Competition 50088 2University of Maryland Company Trauma Solutions Named Finalist in 24250K Draper Fisher Jurvetson and Cisco Systems Global Business Plan Competition 50088 3Abused Kids Face Higher Cancer Risk 50083 1Abused Kids Face Higher Cancer Risk 50083 2The AGA Foundation awards grant to Dr Michael Choi to further his research on carcinoid tumors 50078 1The AGA Foundation awards grant to Dr Michael Choi to further his research on carcinoid tumors 50078 2
Other Contentsprincipleprincipleprincipleprincipleprincipleprincipleprincipleprincipleprinciplehardyhepatitishepatitishepatitishepatitishepatitishepatitishepatitishepatitishelperhelperhelperhelperhelperhelperherbivorehermaphrodite